WF-47-JS03 |
Katalog-Nr.GC61381 |
WF-47-JS03 ist ein potenter und selektiver RET-Kinase-Inhibitor mit IC50-Werten von 1,7 nM und 5,3 nM fÜr KIF5B-RET-transfizierte Ba/F3-Zellen bzw. CCDC6-RET-transfizierte LC-2/ad-Lungenkrebszellen. WF-47-JS03 zeigt eine >500-fache SelektivitÄt gegenÜber dem Kinase-InsertdomÄnenrezeptor (KDR). Effektive Gehirndurchdringung.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2561413-77-0
Sample solution is provided at 25 µL, 10mM.
WF-47-JS03 is a potent and selective RET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells, CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration[1].
WF-47-JS03 inhibits Tel-KDR transfected Ba/F3 cells, and Ba/F3 wild-type cell lines with IC50s of 0.99 and 1.5 μM, respectively[1].
WF-47-JS03 significantly inhibits tumor growth in RIE KIF5B-RET xenograft mice and is well tolerated at 1, 3, and 10 mg/kg in the 10 day study[1]. Animal Model: Female 6-8 week old Harlan Foxn1 nude mice with RIE-RET-KIF5B transgenic cell line
[1]. Casey J N Mathison , et al. Efficacy and Tolerability of Pyrazolo[1,5- a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma. ACS Med Chem Lett. 2020 Feb 12;11(4):558-565.
Average Rating: 5
(Based on Reviews and 22 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *